Raymond James Financial, Inc. (NYSE:RJF) saw its shares rise today after several bullish analyst moves and earnings estimate upgrades. Positive drivers include a higher price target from Wells Fargo and raised EPS forecasts from Seaport Res Ptn, while new coverage on Vir Biotechnology and international share-price updates remain neutral.
Positive Sentiment:
Wells Fargo & Company boosted its price target for RJF to $163 (from $155) and maintained an “equal weight” rating, pointing to roughly 2.8% upside. Wells Fargo Forecast
Positive Sentiment:
Seaport Res Ptn raised its FY2025 EPS estimate for RJF to $10.40 (from $10.30) and lifted its Q4 2025 and Q2 2026 EPS forecasts. Bullish FY2025 Outlook
Positive Sentiment:
Seaport Res Ptn also upped its Q1 2026 EPS forecast to $2.90 (from $2.89), nudging full-year estimates slightly higher. Q1 2026 EPS Upgrade
Neutral Sentiment:
Raymond James initiated coverage on Vir Biotechnology (VIR) with a positive outlook, reflecting research‐service growth. Coverage of VIR
Neutral Sentiment:
A London South East page updated RJF.B.US share-price data for U.K. investors. London South East Quote
Posted 1+ days ago
AI Generated. May Contain Errors.